Onkologie. 2015:9(4):199-201

Adjuvant chemotherapy in high-risk endometrial carcinoma

Renata Soumarová^1,2,3, Markéta Těžká¹, Dana Vráblová¹, Lenka Teglová¹, Pavel Bartoš⁴, Martin Trhlík⁴, Robert Bučko⁴

¹ Oddělení radioterapie a onkologie, Nemocnice Nový Jičín a.s. a Komplexní onkologické centrum Nový Jičín

² Katedra interních oborů, Lekařská fakulta Ostravské univerzity v Ostravě

³ Onkologické oddělení, Vzdělávací a výzkumný institut Agel o.p.s., Nemocnice Nový Jičín a.s.

⁴ Oddělení gynekologie, Nemocnice Nový Jičín a.s. a Komplexní onkologické centrum Nový Jičín

Surgical treatment is the gold standard for treating endometrial carcinoma. Adjuvant radiotherapy in the form of brachytherapy or external

radiotherapy is indicated in moderate and high-risk carcinoma where it particularly reduces the rate of locoregional recurrence.

In high-risk carcinoma, however, patients are also at risk of disease generalization, which is the reason for considering the inclusion of

adjuvant chemotherapy in the treatment regimen. Chemotherapy can be used concomitantly with radiotherapy as concomitant chemoradiotherapy

or sequentially after radiotherapy termination. The article describes the results of papers that have utilized adjuvant

chemotherapy. The results have not been entirely unequivocal so far, and the conclusions of large studies are yet to be published. Still,

in high-risk endometrial carcinoma, the use of chemotherapy is currently taken into consideration in the clinical practice.

Keywords: high-risk endometrial carcinoma, adjuvant chemotherapy, chemoradiotherapy

Published: September 18, 2015  Show citation